N2OFF amends MitoCareX acquisition: extends closing deadline, updates share counts and consideration caps

Nexentis Technologies Inc.

Outside Date extended by 90 days to 270 days from original agreement date (Feb 25, 2025).
Fully-diluted share count updated to 32,808,629 (from 27,734,248) to reflect issuances after execution.
Additional consideration for sellers capped at $1.6M total, allocated 52.73% SciSparc, 31.51% Alon, 15.76% Ciro.
Post-closing N2OFF shares outstanding projected at 56,939,836, up from current 30,096,412 (increase ~26.8M).
Milestone-based Additional Purchaser Stock of up to 25% of post-closing fully-diluted capital, vesting by Dec 31, 2028.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.